Public Health Impact of Targeted Tuberculosis Screening in Public Schools

Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.

Public Health Impact of Targeted Tuberculosis Screening in Public Schools

American Journal of Public Health (12.02) No. 12; Vol. 92: P. 1942-1945 - Thursday, December 26, 2002
Soju Chang, MD, MPH; Lani S.M. Wheeler, MD, FAAP; and Katharine P. Farrell, MD, MPH

People born where TB is prevalent are at higher risk of contracting the disease. In Anne Arundel County, Md., where only 3 percent of the population is foreign-born, foreign-born persons comprised 40 percent of active TB cases in 1998.

In 1987, two foreign-born students in the Anne Arundel County public school system contracted active pulmonary TB. Thirty- five school contacts developed latent TB infection (LTBI). Two years later, the county Department of Health, in collaboration with the public school system, instituted a policy of targeted screening, with the tuberculin skin test (TST) of all foreign- born students entering public schools, under the guidelines of the American Academy of Pediatrics, the Advisory Committee for Elimination of Tuberculosis of CDC and the American Thoracic Society.

Students born outside the United States, even American citizens, must show TST documentation before enrolling in school. Those with a history of TB must show documentation of treatment.

In 1999, the county Department of Health reviewed data on students the department had screened from 1993 to 1998 to evaluate the impact of targeted TB screening. In that time period, 706 foreign-born students took TSTs. One hundred sixteen were positive (median age 14) and 590 were negative (median age 10). Physicians evaluated students with positive TSTs, and the students received chest x-rays. Median time between TST readings and x-rays was 26 days. Only one student had active TB. One hundred seven of the 115 candidates eligible for LTBI took isoniazid under parental supervision. Six students refused treatment, and two candidates, contacts of a child with isoniazid-resistant TB, took rifampin. Adherence rate to the treatment was 90 percent.

The authors estimate that without treatment, 11 cases of active TB would have occurred during the lifetimes of those with LTBI. About six to eight cases were averted with isoniazid treatment, assuming an isoniazid efficacy of 69-99 percent in children, the study reports.

Economically, staff salaries and benefits accounted for 85 percent of the intervention cost, an estimated $32,617 for six years. The researchers estimated the potential cost of lifetime disease averted at $98,350, giving a net savings of $65,733. "From the societal long-term perspective," the study reports, "$2 was saved for every $1 invested."

The authors concluded that, "As US rates decline, the treatment of LTBI and the control of imported TB become priorities. Despite its limitations, targeted school screening followed by LTBI treatment can be cost-effective against TB in recent immigrants (< five years). This study offers further support for the recommendations of the American Academy of Pediatrics, the CDC and the American Thoracic Society."
021226
AD022491

Copyright © 2002 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.